- Wetteny Joseph became group president of Catalent’s Pharma and Consumer Health business on Nov. 2.
- The segment covers oral delivery manufacturing and advanced delivery systems for self-care products.
Catalent, a Tampa, Florida-based global CDMO serving pharmaceutical, biotech and consumer health companies, appointed Wetteny Joseph as group president of its Pharma and Consumer Health segment effective Nov. 2, 2026. He joined the company’s Group Executive Committee and reports directly to President and CEO Alessandro Maselli.
Joseph will oversee oral delivery technologies and manufacturing for small and macromolecules, together with advanced delivery systems for self-care products. Catalent’s Self Care business includes dietary supplements, over-the-counter medicines, and skin, hair and fragrance products within a network of nearly 40 global sites. The company says the broader organization produces 60 billion treatment doses annually across drug and self-care formats.
He joins Catalent from Zoetis, where he served as executive vice president and chief financial officer with responsibility for financial management, planning, operations, indirect procurement and the animal-health company’s Human Health Diagnostics business. Joseph previously held senior Catalent roles including chief financial officer and president of Clinical Supply Services.
Joseph succeeds Aris Gennadios, who is leaving after a Catalent career that began in 2002 to pursue outside opportunities. The company did not announce related changes to Pharma and Consumer Health manufacturing sites, capacity or investment. Maselli described Joseph’s prior company experience as central to the appointment.
“Wetteny is an accomplished leader with a deep understanding of our industry, our customers and Catalent.”
Alessandro Maselli, president and CEO, Catalent
